FDA officials say that the fees, which e-cigarette companies would pay when filing applications with the agency, would give regulators resources to tackle the thousands of illegal vapes lining ...

“The FDA has decided not to pursue a menthol cigarette or a flavored cigar ... tobacco applications for NJoy menthol e-cigs and for Vuse Alto. “We think the FDA will refocus back on harm ...

In September, the U.S. Food and Drug Administration (FDA) told industry that it would begin enforcing the agency’s cigarette graphic warning rule in December 2025 in an enforcement policy ...

The director of the FDA's Center for ... (19.9%), Mr. Fog (15.8%), Vuse (13.7%) and JUUL (12.6%)." The report said the biggest drop was in the use of Elf Bar brand e-cigarette products, down ...

According to Arizton’s latest research report, the e-cigarette ... traditional cigarette sales. Successful innovations, such as Philip Morris International's IQOS and BAT's Vuse, have gained ...

according to the survey “The continued decline in e-cigarette use among our nation’s youth is a monumental public health win,” FDA Center for Tobacco Products Director Brian King said in a ...

The FDA faces increasing pressure to finish reviewing applications from companies seeking to market e-cigarette products. The agency in June approved the first menthol-flavored e-cigarettes — a ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis ...

Estimates of e-cigarette and nicotine pouch use among youth are based on data from the National Youth Tobacco Survey, published Thursday by the CDC and the FDA. A nationally representative sample ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed ...